ReviewACS applied materials & interfaces2026
Synergy between Antimicrobial Peptides and Lipid Nanoparticles for Skin Infection Control.
Review in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.Discover nano · 2026Review
- Plant-Derived Peptide-Polymer Therapeutics for Cutaneous Infections and Inflammation: Mechanistic Basis, Delivery Design and Translational Considerations.Pharmaceutics · 2026Review
- Antimicrobial Peptide Sublancin Skin Sensitization and Irritation Assessment in Guinea Pigs and Rabbits.Toxics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin infections caused by multidrug-resistant bacteria are an increasing public health concern, requiring therapeutic approaches. Antimicrobial peptides (AMPs) have been studied as alternatives to conventional antibiotics due to their broad-spectrum activity and lower risk of inducing resistance. However, their clinical application remains limited due to enzymatic instability, rapid clearance, and potential toxicity. Lipid nanoparticles (LNPs) have emerged as a promising strategy to protect and deliver AMPs in a controlled manner, enhancing their efficacy while reducing side effects. This review explores how AMP encapsulation within LNPs can improve stability, prolong antimicrobial activity, and optimize skin penetration. Despite recent advances, challenges, such as scalability, regulatory approval, and clinical application, must still be addressed to bring this approach into widespread use for skin infection treatment. This review explores the synergy between AMPs and LNPs, focusing on their mechanisms of action,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.